REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

BRIM Biotechnology, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: BRIM Biotechnology, Inc. Profile Updated: March 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

BRIM Biotechnology, Inc. is engaged in the research and development of innovative medicines. The main products of company include Dry Eye Syndrome, Severe Cornea Damage, Neurotrophic Keratitis(NK), Osteoarthritis. The company was established in 2013 and is headquartered in Taipei City, Taiwan.

Headquarters
8F, No.1, Alley 30, Lane358, Ruiguang Rd, Neihu Dist
Taipei City; Taipei City;

Contact Details: Purchase the BRIM Biotechnology, Inc. report to view the information.

Website: http://www.brimbiotech.com

Basic Information
Total Employees:
Purchase the BRIM Biotechnology, Inc. report to view the information.
Outstanding Shares:
Purchase the BRIM Biotechnology, Inc. report to view the information.
Financial Auditors:
Purchase the BRIM Biotechnology, Inc. report to view the information.
Incorporation Date:
July 31, 2013
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
12.87%
Purchase this report to view the information.
2.37%
Purchase this report to view the information.
0.48%
Purchase this report to view the information.
0.14%
Purchase this report to view the information.
0.09%
Subsidiaries
ASCENDO BIOTECHNOLOGY, INC. TAIWAN BRANCH
19.55%
Company Performance
Financial values in the chart are available after BRIM Biotechnology, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-36.63%▼
EBITDA
-13.68%▼
Net Profit (Loss) for the Period
-13.88%▼
Total assets
120.09%▲
Total equity
121.44%▲
Return on Equity (ROE)
19.93%▲
Quick Ratio
6.76%▲
Cash Ratio
6.81%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo